Both methods are employed at central testing labs for prospective or retrospective identification of the AKT1 E17K mutation in ER+ breast cancer patients in the context of a clinical trial testing the AKT inhibitor AZD5363 in combination with endocrine (fulvestrant) therapy. This evidence concerns the gene AKT1 and breast cancer.